Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Geneva, Switzerland - 24 March 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder and Tim ADAMS, CFO, will attend the 16th Annual Needham Healthcare Conference. Management will be presenting on Tuesday April 4 at 3:40 pm and will be hosting one-on-one meetings on April 4 and 5, 2017 at the Westin New York Grand Central Hotel.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Company Contact:
Delphine Renaud
ObsEva, CEO Office
[email protected]
+41 22 552 1550
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/571924da-1372-41eb-98ea-95ecb31fd84b
